MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.jpeds.2025.114889

Медицинская библиотека · The Journal of pediatrics · 2025

Rapid Genome Sequencing Compared with a Gene Panel in Critically Ill Infants with a Suspected Genetic Disorder: An Economic Evaluation.

Lavelle Tara A, Maron Jill L, Kingsmore Stephen F, Lin Ching-Hsuan, Zhu Yingying, Sweigart Benjamin, Reed Dallas, Gelb Bruce D, Vockley Jerry, Davis Jonathan M

СтатьяМногоцентровое исследованиеСравнительное исследованиеПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

OBJECTIVE

To compare 1-year health care costs and quality-adjusted life years (QALYs) for 2 diagnostic strategies in critically ill infants with suspected genetic disorders: 1) early rapid genome sequencing (rGS; within 7 days of admission) for all infants, and 2) early targeted neonatal gene sequencing (NewbornDx) for all infants, followed by later rGS (after 7 days) for undiagnosed infants.

STUDY

DESIGN

The Genomic Medicine for Ill Neonates and Infants study was a multicenter, prospective study that enrolled 400 hospitalized infants under 1 year of age with suspected genetic disorders. All participants underwent both rGS and NewbornDx. Using patient-level Genomic Medicine for Ill Neonates and Infants data and 2023 Medicare rates, we developed a decision tree to compare total costs and QALYs over a 1-year period for these 2 hypothetical testing strategies.

RESULTS

The diagnostic yield and upfront testing costs were higher for rGS (49%; $12,297) than NewbornDx (27%; $2449; P < .05). As neither early testing nor diagnosis significantly affected QALYs, we conducted a cost-minimization analysis, focusing solely on cost differences between strategies. Over 1 year, early rGS was estimated to save $158,592 per patient (95% CI: $63,701-$253,292) compared with early NewbornDx with later rGS if necessary.

CONCLUSIONS

Early rGS results in substantial health care cost savings, highlighting the need to expand reimbursement to improve access early in a hospitalization for critically ill infants.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03890679.

Для цитирования: Lavelle Tara A, Maron Jill L, Kingsmore Stephen F, Lin Ching-Hsuan, Zhu Yingying, Sweigart Benjamin, Reed Dallas, Gelb Bruce D, Vockley Jerry, Davis Jonathan M. Rapid Genome Sequencing Compared with a Gene Panel in Critically Ill Infants with a Suspected Genetic Disorder: An Economic Evaluation.. The Journal of pediatrics. 2025. DOI: 10.1016/j.jpeds.2025.114889.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.